TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

China's COVID-19 vaccine candidate shows promise in human trials, CNBG says

  • News Desk

    Reuters

Beijing, China/Singapore   /   Thu, June 18, 2020   /   01:00 pm
China's COVID-19 vaccine candidate shows promise in human trials, CNBG says This image obtained March 12, 2020 courtesy of The National Institutes of Health(NIH)/NIAD-RML shows a scanning electron microscope image of SARS-CoV-2 (round blue objects) emerging from the surface of cells cultured in the lab, SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19, the virus shown was isolated from a patient in the US.China National Biotec Group (CNBG) said on Tuesday its experimental coronavirus vaccine has triggered antibodies in clinical trials and the company plans late-stage human trials in foreign countries. (Handout/National Institutes of Health/AFP/File)

China National Biotec Group (CNBG) said on Tuesday its experimental coronavirus vaccine has triggered antibodies in clinical trials and the company plans late-stage human trials in foreign countries.

No vaccines have been solidly proven to be able to effectively protect people from the virus that has killed more than 400,000 people, while multiple candidates are in various stages of development globally.

The vaccine, developed by a Wuhan-based research institute affiliated to CNBG's parent company China National Pharmaceutical Group (Sinopharm), was found to have induced high-level antibodies in all inoculated people without serious adverse reaction, according to the preliminary data from a clinical trial initiated in April involving 1,120 healthy participants aged between 18 and 59.

CNBG said it is proactively seeking opportunities for late-stage and large-scale Phase 3 trials overseas.

"have secured cooperative intent with companies and institutes in many countries," the company said in a statement.

State media reported that the vaccine candidate, along with a different experimental shot developed by Sinopharm's unit, has been offered to Chinese employees at state-owned firms travelling overseas as developers seek more data on their efficacy.

China has five vaccine candidates for COVID-19 in human trials, the most in any country.

China's vaccine maker Sinovac Biotech (Sinovac) released over the weekend positive preliminary clinical trial results for its potential vaccine candidate, which is expected to be tested in a Phase 3 trial in Brazil.